Enliven Therapeutics, Inc. (ELVN)
41.14
-0.38
(-0.92%)
USD |
NASDAQ |
Oct 26, 10:41
Enliven Therapeutics Price to Book Value : 3.367 for Oct. 26, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 3.398 |
| October 22, 2026 | 3.431 |
| October 21, 2026 | 3.422 |
| October 20, 2026 | 3.376 |
| October 19, 2026 | 3.167 |
| October 16, 2026 | 3.054 |
| October 15, 2026 | 3.218 |
| October 14, 2026 | 3.214 |
| October 13, 2026 | 3.232 |
| October 12, 2026 | 3.342 |
| October 09, 2026 | 3.354 |
| October 08, 2026 | 3.325 |
| October 07, 2026 | 3.385 |
| October 06, 2026 | 3.469 |
| October 05, 2026 | 3.721 |
| October 02, 2026 | 3.844 |
| October 01, 2026 | 3.781 |
| September 30, 2026 | 3.751 |
| September 29, 2026 | 3.806 |
| September 28, 2026 | 3.765 |
| September 25, 2026 | 3.662 |
| September 24, 2026 | 3.696 |
| September 23, 2026 | 3.772 |
| September 22, 2026 | 3.944 |
| September 21, 2026 | 3.999 |
| Date | Value |
|---|---|
| September 18, 2026 | 4.047 |
| September 17, 2026 | 4.111 |
| September 16, 2026 | 4.020 |
| September 15, 2026 | 4.366 |
| September 14, 2026 | 4.454 |
| September 11, 2026 | 4.445 |
| September 10, 2026 | 4.601 |
| September 09, 2026 | 4.701 |
| September 08, 2026 | 4.858 |
| September 04, 2026 | 4.854 |
| September 03, 2026 | 4.881 |
| September 02, 2026 | 4.829 |
| September 01, 2026 | 4.735 |
| August 31, 2026 | 4.737 |
| August 28, 2026 | 4.735 |
| August 27, 2026 | 4.951 |
| August 26, 2026 | 4.981 |
| August 25, 2026 | 4.993 |
| August 24, 2026 | 5.004 |
| August 21, 2026 | 4.895 |
| August 20, 2026 | 4.822 |
| August 19, 2026 | 4.86 |
| August 18, 2026 | 4.916 |
| August 17, 2026 | 4.872 |
| August 14, 2026 | 4.813 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Definium Therapeutics, Inc. | 5.195 |
| Cocrystal Pharma, Inc. | 12.68 |
| CNBX Pharmaceuticals, Inc. | -- |
| Arvinas, Inc. | 0.8549 |
| Fulcrum Therapeutics, Inc. | 0.9010 |
Price to Book Value Related Metrics
| Price | 41.14 |
| Earnings Yield | -4.06% |
| Market Cap | 3.014B |